Evidence map›Paper›PMID 42056573›Full record

ArticleApplied microbiology and biotechnology2026

Isolation and genomic characterization of a lytic bacteriophage against multidrug-resistant Proteus mirabilis.

Parmanand Kushwaha, Sovon Acharya, Manisha Behera, Shailesh Desai, Surajit Gandhi, Munindra Ruwali, Lakshminarasimhan Krishnaswamy, Sarika Chaturvedi, Sachinandan De, Prashanth Suravajhala and 1 more

Abstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Parmanand KushwahaAmity Institute of Biotechnology, Amity University, Gurgaon, 122413, India. parmanand.mhg.bhu16@gmail.com.
Sovon AcharyaAmity Institute of Biotechnology, Amity University, Gurgaon, 122413, India.
Manisha BeheraDepartment of Zoology, Hindu College, University of Delhi, Delhi, 110007, India.
Shailesh DesaiDepartment of Zoology, Banaras Hindu University, Banaras, UP, 221005, India.
Surajit GandhiInstitute of Life Science, Bhubaneswar, India.
Munindra RuwaliDepartment of Education in Science and Mathematics (DESM), National Council of Educational Research and Training (NCERT), New Delhi, India.
Lakshminarasimhan KrishnaswamyAmity Institute of Biotechnology, Amity University, Gurgaon, 122413, India.
Sarika ChaturvediAmity Institute of Biotechnology, Amity University, Gurgaon, 122413, India.
Sachinandan DeAnimal Genomics Lab, Animal Biotechnology Centre, ICAR-National Dairy Research Institute (NDRI), Karnal, 132001, Haryana, India.
Prashanth SuravajhalaDepartment of Biosciences, Manipal University Jaipur, Dehmi Kalan, Rajasthan, Jaipur, 303007, India. prash.s@jaipur.manipal.edu.
Gyaneshwer ChaubeyDepartment of Zoology, Banaras Hindu University, Banaras, UP, 221005, India. gyaneshwer.chaubey@bhu.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant (MDR) Proteus mirabilis is a significant opportunistic pathogen, largely due to its ability to form robust biofilms that are recalcitrant to conventional antibiotic therapy. Bacteriophages represent a promising alternative, yet their therapeutic potential is contingent on a thorough characterization of their biological functions and genomic architecture. This study details the isolation and comprehensive analysis of a novel bacteriophage targeting MDR P. mirabilis. A novel lytic bacteriophage, designated Proteus phage ram_arti_1324, was isolated from sewage. Transmission electron microscopy classified it as a member of the family Podoviridae. Functional assays demonstrated its potent efficacy against established P. mirabilis biofilms, achieving a 55% reduction in total biomass in vitro conditions. Whole-genome sequencing revealed a linear, double-stranded DNA genome of 91,735 bp with a GC content of 34.7%. Genomic annotation identified 146 putative coding sequences (CDS), including key lytic genes encoding two distinct endolysins, and four tRNA genes. Crucially, the genome lacks any identifiable virulence factors, antibiotic resistance genes, or markers indicative of a lysogenic life cycle. Comparative genomic analysis against 51 known Proteus phages confirmed its novelty. Proteus phage ram_arti_1324 shares less than 95% average nucleotide identity with its closest relatives, suggesting it represents a novel viral species. This uniqueness was further supported by whole-genome alignment, which revealed a distinct arrangement of locally co-linear blocks not observed in other related phages. The genomic and functional data establish that Proteus phage ram_arti_1324 is a novel, strictly lytic bacteriophage with significant therapeutic potential against both planktonic and biofilm-associated MDR P. mirabilis. Its potent anti-biofilm activity, combined with a genome free of deleterious genes, makes it a strong candidate for further development in phage-based clinical applications. The complete genome sequence provides a valuable resource for future research into phage-host dynamics and the bioengineering of next-generation antimicrobial agents. KEY POINTS: • Novel lytic bacteriophage Proteus phage ram_arti_1324 was isolated with genome size 91735 bp. • Proteus phage ram_arti_1324 displayed absence of virulence factors, antibiotic resistance genes (ARGs) and deleterious genes. • Proteus phage ram_arti_1324 displayed antibiofilm activity against MDR P. mirabilis.

Indexed as

BacteriophagesDrug Resistance, Multiple, BacterialGenome, ViralPodoviridaeProteus mirabilisBase CompositionBiofilmsDNA, ViralGenomicsSewageWhole Genome SequencingDNA, ViralSewageAntimicrobial resistanceBacteriophageBiofilmPodoviridaeProteus mirabilis

Identifiers

PMID42056573
PMCPMC13272245

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.